Today’s biopharma news highlights how new data could reduce treatment burden, improve excipient information sharing, and shape future options for patients with difficult-to-treat cancers.
|Articles|May 1, 2017
EAG Laboratories
Advertisement
EAG Laboratories: Complete biopharmaceutical characterization services
EAG Laboratories’ complete suite of biopharmaceutical characterization services include: Mass analysis (intact, reduced, deglycosylated); Peptite Map-UPLC-UHR QT of MS (Sequencing, PTMs, Disulfide Linkages, Chemical Modification for ADC , PEG, etc.); N-Glycan Profile-UPLC-MS, HI LIC -FL (site, extent and structure of glycosylation); and Protein structure characterization, analysis of post-translational modifications and degradants, and glycosylation analysis.
+1.800.538.5227
Advertisement
Related to this article
Daiichi Sankyo and Merck pulled ifinatamab deruxtecan's FDA filing in small cell lung cancer after a 187-patient trial fell short.
IPEC’s EIP user guide streamlines information exchange and response times while increasing accuracy through standardization.
Insulin efsitora alfa-gobe (Onswik) cuts injections from 365 to 52 a year for adults with type 2 diabetes, per its new FDA approval.
Genentech is paying Earendil Labs $55 million upfront in a deal worth over $1.5 billion to develop bispecific antibodies for hard-to-treat cancers.
Acuitas CEO Dr Thomas Madden and NanoVation co-founder and president Dr Dominik Witzigmann discuss how LNP engineering is expanding genetic medicine applications to traditionally undruggable targets.
Guselkumab eased spinal pain, stiffness, and MRI-confirmed spinal inflammation in a 411-patient trial of psoriatic arthritis with axial involvement.
AstraZeneca's sBLA for durvalumab combined with neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer, based on the Phase 3 VOLGA trial, has a PDUFA date expected in the fourth quarter of 2026.
Advertisement
Advertisement